Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Brainstorm Cell Therapeutics Inc./ 8-K

Current Report · Items 2.02, 9.01 · 8-K

Brainstorm Cell Therapeutics Inc.

BCLIOTCEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On August 14, 2026, Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.…

Filed Aug 14, 2026Accepted Aug 14, 2026, 4:16 PM EDTCIK 1137883Accession 0001104659-26-097180
View company →Permanent SEC source ↗
Share

Company context

BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company’s proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.

Current securities

BCLIOTC · EQUITY · Current

Recent company filings

  1. 10-Q filingAug 14, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureJul 30, 2026
  3. EFFECT filingJun 2, 2026
  4. 4 filingMay 29, 2026
  5. 4 filingMay 29, 2026

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition. On August 14, 2026, Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 (by filename) tm2623188d1_ex99-1.htm

EX-99.1 2 tm2623188d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, Aug 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update. “We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment,” said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. “The recent appointment of Peter Pitts as Executive Chairman represents an important enhancement to our leadership. Peter is joining the Company in an active executive capacity and will help lead the regulatory, operational, partnership and capital-markets initiatives surrounding the NurOwn program. His experience as a former senior FDA official brings an additional level of regulatory insight and strategic perspective as we prepare to enter this next phase. ALS impose…

Open exhibit ↗